Respicardia Inc

Respicardia Inc, acquired by ZOLL in 2021, is a leading company specializing in innovative technologies for the treatment of Central Sleep Apnea (CSA) in adults. Their flagship product, the remed System, is an implantable phrenic nerve stimulator that restores a more normal breathing pattern during sleep, effectively addressing the harmful effects of CSA. Founded in 2006, Respicardia is dedicated to improving the quality of life and overall health of individuals suffering from CSA, a serious breathing disorder resulting from the brain's inability to send appropriate signals to the respiratory muscles.

With FDA approval and advanced technology, the remed System offers a breakthrough solution for moderate to severe CSA. It is MR Conditional, making it safe for use in patients, and can be used alongside other stimulation devices after special testing. While there are risks associated with the surgical procedure and the presence of the device, the majority of discomfort and side effects can be resolved through adjustments to therapy settings. Respicardia's mission is to provide effective treatment options for CSA, enhancing the well-being of patients and offering hope for a better quality of life.

Generated from the website